目的 探討整合蛋白α5β1和微血管密度在胃癌組織中表達的臨床意義及其相互關(guān)系。方法采用免疫組化SP法檢測了35例胃癌組織及其中10例胃癌淋巴結(jié)轉(zhuǎn)移灶和8例慢性淺表性胃炎組織中整合蛋白α5β1的表達及微血管密度(MVD)。結(jié)果胃癌組織中整合蛋白α5β1表達水平及MVD均顯著高于慢性胃炎(t=3.32, P<0.01; t=2.30, P<0.05); 胃癌原發(fā)灶中整合蛋白α5β1的表達僅與胃癌浸潤深度相關(guān)(t=2.29, P<0.05),而MVD則與胃癌浸潤深度、淋巴結(jié)有無轉(zhuǎn)移及TNM分期之間密切相關(guān)(t=3.07,P<0.01; t=2.48,P<0.05; t=2.94,P<0.01); 胃癌淋巴結(jié)轉(zhuǎn)移灶中整合蛋白α5β1表達水平較相應的原發(fā)灶顯著增高(t=2.45, P<0.05); 整合蛋白α5β1的表達及MVD均與胃癌組織學分級無關(guān)(t=0.15,P gt;0.05; t=0.41, P gt;0.05); 胃癌組織中整合蛋白α5β1不同表達水平間MVD的差異無顯著性意義(F=1.43, P gt;0.05),相關(guān)性分析顯示兩者無顯著相關(guān)性(r=0.156, P=0.37)。 結(jié)論整合蛋白α5β1在胃癌組織中的表達顯著上調(diào)并與胃癌的進展有關(guān),有可能成為判斷胃癌侵襲和轉(zhuǎn)移能力的指標及基因治療的靶標,其在胃癌血管生成中可能無重要作用。
引用本文: 周業(yè)江,時德,吳斌. 整合蛋白α5β1的表達與胃癌生物學行為及微血管密度的關(guān)系. 中國普外基礎(chǔ)與臨床雜志, 2003, 10(3): 256-259. doi: 復制
1. | 雷雯,郁寶銘,周錫庚,等. 大腸癌組織中微血管定量檢測的臨床價值 [J]. 中國普外基礎(chǔ)與臨床雜志, 2002; 9(1)∶ 40. |
2. | Kawahara E, Ooi A, Nakanishi I. Integrin distribution in gastric carcinoma: association of beta 3 and beta 5 integrins with tumor invasiveness [J]. Pathol Int, 1995; 45(7)∶493. |
3. | 蘇劍敏,王麗影,桂津,等. FAK和整合蛋白α5β1亞基在胃癌中表達的比較及其臨床意義 [J]. 中華實驗外科雜志,2001; 18(4)∶ 315. |
4. | Gong J, Wang D, Sun L, et al. Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells [J]. Cell Growth Differ, 1997; 8(1)∶ 83. |
5. | 方新初,蘇劍敏,周國飛,等. 整合蛋白α5β1亞基的過表達對肝癌細胞粘附和遷移的影響 [J]. 中國癌癥雜志,2001; 11(1)∶ 1. |
6. | 夏加增,朱正綱,燕敏,等. 胃癌血管生成及其與周圍靜脈血微轉(zhuǎn)移的關(guān)系 [J]. 中華外科雜志, 2001; 39(7)∶ 511. |
7. | Senger DR, Claffey KP, Benes JB, et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins [J]. Pro Natl Acad Sci USA, 1997; 94(25)∶ 13612. |
8. | Carron CP, Meyer DM, Pegg JA, et al. A peptidomimetic antagonist of the integrin αvβ3 inhibits leydig cell tumor growth and development of hypercalcemia of malignancy [J]. Cancer Res,1998; 58(9)∶ 1930. |
9. | Kim S, Bell K, Mousa SA, et al. Regulation of angiogenesis in vivo by ligation of integrin alpha 5 beta 1 with the central cellbinding domain of fibronectin [J]. Am J Patho, 2000; 156(4)∶ 1345. |
- 1. 雷雯,郁寶銘,周錫庚,等. 大腸癌組織中微血管定量檢測的臨床價值 [J]. 中國普外基礎(chǔ)與臨床雜志, 2002; 9(1)∶ 40.
- 2. Kawahara E, Ooi A, Nakanishi I. Integrin distribution in gastric carcinoma: association of beta 3 and beta 5 integrins with tumor invasiveness [J]. Pathol Int, 1995; 45(7)∶493.
- 3. 蘇劍敏,王麗影,桂津,等. FAK和整合蛋白α5β1亞基在胃癌中表達的比較及其臨床意義 [J]. 中華實驗外科雜志,2001; 18(4)∶ 315.
- 4. Gong J, Wang D, Sun L, et al. Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells [J]. Cell Growth Differ, 1997; 8(1)∶ 83.
- 5. 方新初,蘇劍敏,周國飛,等. 整合蛋白α5β1亞基的過表達對肝癌細胞粘附和遷移的影響 [J]. 中國癌癥雜志,2001; 11(1)∶ 1.
- 6. 夏加增,朱正綱,燕敏,等. 胃癌血管生成及其與周圍靜脈血微轉(zhuǎn)移的關(guān)系 [J]. 中華外科雜志, 2001; 39(7)∶ 511.
- 7. Senger DR, Claffey KP, Benes JB, et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins [J]. Pro Natl Acad Sci USA, 1997; 94(25)∶ 13612.
- 8. Carron CP, Meyer DM, Pegg JA, et al. A peptidomimetic antagonist of the integrin αvβ3 inhibits leydig cell tumor growth and development of hypercalcemia of malignancy [J]. Cancer Res,1998; 58(9)∶ 1930.
- 9. Kim S, Bell K, Mousa SA, et al. Regulation of angiogenesis in vivo by ligation of integrin alpha 5 beta 1 with the central cellbinding domain of fibronectin [J]. Am J Patho, 2000; 156(4)∶ 1345.